Презентация The global burden of postpartum haemorrhage. Postpartum haemorrhage (PPH) is the leading cause of maternal death worldwide онлайн

На нашем сайте вы можете скачать и просмотреть онлайн доклад-презентацию на тему The global burden of postpartum haemorrhage. Postpartum haemorrhage (PPH) is the leading cause of maternal death worldwide абсолютно бесплатно. Урок-презентация на эту тему содержит всего 33 слайда. Все материалы созданы в программе PowerPoint и имеют формат ppt или же pptx. Материалы и темы для презентаций взяты из открытых источников и загружены их авторами, за качество и достоверность информации в них администрация сайта не отвечает, все права принадлежат их создателям. Если вы нашли то, что искали, отблагодарите авторов - поделитесь ссылкой в социальных сетях, а наш сайт добавьте в закладки.
Презентации » Здоровье и Медицина » The global burden of postpartum haemorrhage. Postpartum haemorrhage (PPH) is the leading cause of maternal death worldwide


Оцените!
Оцените презентацию от 1 до 5 баллов!
Смотреть онлайн
Скачать
  • Тип файла:
    ppt / pptx (powerpoint)
  • Всего слайдов:
    33 слайда
  • Для класса:
    1,2,3,4,5,6,7,8,9,10,11
  • Размер файла:
    3.81 MB
  • Просмотров:
    48
  • Скачиваний:
    0
  • Автор:
    неизвестен


Слайды и текст к этой презентации:

№1 слайд
Содержание слайда:
№2 слайд
The global burden of
Содержание слайда: The global burden of postpartum haemorrhage The global burden of postpartum haemorrhage
№3 слайд
What is postpartum
Содержание слайда: What is postpartum haemorrhage? Postpartum haemorrhage (PPH) is the leading cause of maternal death worldwide. Postpartum haemorrhage (PPH) is commonly defined as a blood loss of 500 ml or more within 24 hours after birth. It affects about 5% of all women giving birth around the world. Globally, nearly one quarter of all maternal deaths are associated with PPH. In most low-income countries, it is the main cause of maternal mortality.
№4 слайд
New findings on uterotonics
Содержание слайда: New findings on uterotonics for PPH prevention 2. Uterotonics for PPH prevention
№5 слайд
New findings on uterotonics
Содержание слайда: New findings on uterotonics for PPH prevention 2. Uterotonics for PPH prevention
№6 слайд
A systematic approach The
Содержание слайда: A systematic approach The recommendations were updated according to the standards of the WHO handbook on guideline development
№7 слайд
GDG formulates the
Содержание слайда: GDG formulates the recommendations The Guideline Development Group (GDG) convened in September & October 2018 The GDG comprised 18 external experts and relevant stakeholders with expertise in research, guideline development, policy and programmes on PPH prevention and treatment.
№8 слайд
What works? Efficacy and
Содержание слайда: What works? Efficacy and safety of uterotonics for PPH prevention uterotonic options vs placebo or no treatment 4. What are the updated WHO recommendations?
№9 слайд
Recommendation . The use of
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births. To effectively prevent PPH, only one of the following uterotonics should be used: Oxytocin Carbetocin Misoprostol Ergometrine/methylergometrine Oxytocin and ergometrine fixed-dose combination
№10 слайд
Recommendation . The use of
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births. To effectively prevent PPH, only one of the following uterotonics should be used: Oxytocin Carbetocin Misoprostol Ergometrine/methylergometrine Oxytocin and ergometrine fixed-dose combination
№11 слайд
Recommendation . The use of
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births. To effectively prevent PPH, only one of the following uterotonics should be used: Oxytocin Carbetocin Misoprostol Ergometrine/methylergometrine Oxytocin and ergometrine fixed-dose combination
№12 слайд
Recommendation . The use of
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births. To effectively prevent PPH, only one of the following uterotonics should be used: Oxytocin Carbetocin Misoprostol Ergometrine/methylergometrine Oxytocin and ergometrine fixed-dose combination
№13 слайд
Recommendation . The use of
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births. To effectively prevent PPH, only one of the following uterotonics should be used: Oxytocin Carbetocin Misoprostol Ergometrine/methylergometrine Oxytocin and ergometrine fixed-dose combination
№14 слайд
Recommendation . The use of
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births. To effectively prevent PPH, only one of the following uterotonics should be used: Oxytocin Carbetocin Misoprostol Ergometrine/methylergometrine Oxytocin and ergometrine fixed-dose combination
№15 слайд
Recommendation . The use of
Содержание слайда: Recommendation 1. The use of an effective uterotonic for the prevention of PPH during the third stage of labour is recommended for all births. To effectively prevent PPH, only one of the following uterotonics should be used: Oxytocin Carbetocin Misoprostol Ergometrine/methylergometrine Oxytocin and ergometrine fixed-dose combination Injectable prostaglandins
№16 слайд
How do we compare uterotonics
Содержание слайда: How do we compare uterotonics to one another? 4. Which one: identifying a uterotonic of choice
№17 слайд
Содержание слайда:
№18 слайд
. Which one Summary of
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference) 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№19 слайд
. Which one Summary of
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference) 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№20 слайд
. Which one Summary of
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference) 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№21 слайд
. Which one Summary of
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference) 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№22 слайд
. Which one Summary of
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference) 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№23 слайд
. Which one Summary of
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference) 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№24 слайд
. Which one Summary of
Содержание слайда: 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference) 4. Which one: Summary of judgements comparing uterotonics to oxytocin (reference)
№25 слайд
Recommendation . In settings
Содержание слайда: Recommendation 2. In settings where multiple uterotonic options are available, oxytocin (10 IU, IM/IV) is the recommended uterotonic agent for the prevention of PPH for all births. Vaginal birth or caesarean section Skilled health personnel are required
№26 слайд
Recommendation . In settings
Содержание слайда: Recommendation 3. In settings where oxytocin is unavailable (or its quality cannot be guaranteed), the use of other injectable uterotonics (carbetocin, or if appropriate ergometrine/methylergometrine or oxytocin and ergometrine fixed-dose combination) or oral misoprostol is recommended. Vaginal birth or caesarean section Skilled health personnel are required
№27 слайд
Recommendation . In settings
Содержание слайда: Recommendation 4. In settings where skilled health personnel are not present to administer injectable uterotonics, the administration of misoprostol (either 400 µg or 600 µg PO) by community health care workers and lay health workers is recommended for the prevention of PPH. If skilled health personnel are not present or have not been trained to administer injectable uterotonics, oral misoprostol is preferred
№28 слайд
. What s new wider scope,
Содержание слайда: 5. What’s new: wider scope, more evidence 5. What’s new: wider scope, more evidence
№29 слайд
. So what s new More
Содержание слайда: 5. So what’s new: More recommendations, greater specificity 5. So what’s new: More recommendations, greater specificity
№30 слайд
. implementing the updated
Содержание слайда: 6. implementing the updated WHO recommendations 6. implementing the updated WHO recommendations
№31 слайд
Implementation considerations
Содержание слайда: Implementation considerations Update clinical guidance Develop or revise existing clinical guidelines, protocols or job aids
№32 слайд
Implementation considerations
Содержание слайда: Implementation considerations Quality-certified uterotonics Regulatory, procurement and logistics processes that work
№33 слайд
Contact us
Содержание слайда: Contact us
Скачать все slide презентации The global burden of postpartum haemorrhage. Postpartum haemorrhage (PPH) is the leading cause of maternal death worldwide одним архивом:
Скачать
Похожие презентации